Corcept Therapeutics Incorporated (CORT)

Market Cap	7.35B
Revenue (ttm)	685.45M
Net Income (ttm)	132.51M
Shares Out	106.04M
EPS (ttm)	1.14
PE Ratio	60.67
Forward PE	48.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,418,727
Open	73.30
Previous Close	73.40
Day's Range	69.28 - 73.80
52-Week Range	29.42 - 117.33
Beta	0.15
Analysts	Strong Buy
Price Target	142.00 (+104.88%)
Earnings Date	Jul 28, 2025

About CORT

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 500
• Stock Exchange: NASDAQ
• Ticker Symbol: CORT
• Website: https://www.corcept.com

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Analyst Summary

According to 4 analysts, the average rating for CORT stock is "Strong Buy." The 12-month stock price target is $142.0, which is an increase of 104.88% from the latest price.

Price Target

$142.0

(104.88% upside)

Analyst Consensus: Strong Buy